Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$7.48

-0.38 (-4.83%)

, SLF

Sun Life Financial

$37.95

-0.31 (-0.81%)

10:21
03/14/19
03/14
10:21
03/14/19
10:21

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lexicon (LXRX) downgraded to Sell from Hold at Gabelli with analyst Kevin Kedra citing his expectation that the FDA will reject sotagliflozin in type 1 diabetes by its March 22 PDUFA date following a split AdCom vote in January. 2. Sun Life Financial (SLF) downgraded to Underperformer from Neutral at CIBC. 3. Yum China (YUMC) downgraded to Outperform from Buy at Daiwa with analyst Adrian Chan citing valuation but says long-term growth remains intact. 4. Line Corp. (LN) downgraded to Underperform from Neutral at Credit Suisse. 5. Nabors Industries (NBR) downgraded to Neutral from Buy at Citi with analyst Scott Gruber saying Nabors' free cash flow outlook is weighted towards the second half of 2019, with Q1 likely to be a cash burn of $40M-plus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

LXRX

Lexicon

$7.48

-0.38 (-4.83%)

SLF

Sun Life Financial

$37.95

-0.31 (-0.81%)

YUMC

Yum China

$40.96

-0.01 (-0.02%)

LN

Line Corp.

$34.30

-1.23 (-3.46%)

NBR

Nabors Industries

$3.49

-0.005 (-0.14%)

  • 22

    Mar

  • 26

    Mar

LXRX Lexicon
$7.48

-0.38 (-4.83%)

03/13/19
GABE
03/13/19
DOWNGRADE
GABE
Sell
Lexicon downgraded to Sell from Hold at Gabelli
01/22/19
WEDB
01/22/19
NO CHANGE
Target $36
WEDB
Outperform
Lexicon price target lowered to $36 from $42 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Lexicon to $36 from $42, while reiterating an Outperform rating on the shares as she sees the split AdComm selloff "overdone." On January 17, the Endocrinologic and Metabolic Drug Advisory Committee had a split vote for/against approval of sotagliflozin as potentially the first oral antidiabetic drug used as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes, she notes. The analyst points out that this was the first AdComm for an oral medication for T1D and the non-diabetes experts may have been thinking about T2D A1c drops not on insulin when criticizing the clinical meaningfulness of the 0.2%-0.4% placebo adjusted A1c drop for sotagliflozin. Moussatos also believes the DKA safety issue was "blown out of proportion." Even if FDA issues a CRL on March 22nd to allow more time to develop a RMS or even REMS, the analyst anticipates approval.
03/14/19
GABE
03/14/19
DOWNGRADE
GABE
Sell
Lexicon downgraded to Sell at Gabelli on expected FDA rejection of sotagliflozin
As previously reported, Gabelli analyst Kevin Kedra downgraded Lexicon to Sell from Hold, citing his expectation that the FDA will reject sotagliflozin in type 1 diabetes by its March 22 PDUFA date following a split AdCom vote in January. He believes the FDA is likely to require additional information regarding a risk mitigation strategy to reduce incidences of diabetic ketoacidosis in type 1 patients on sotagliflozin, which is "a manageable hurdle," but one that will likely take additional time to navigate, Kedra tells investors. He has reduced his 2020 private market value estimate for Lexicon shares to $6.00 from $6.50.
01/22/19
SBSH
01/22/19
NO CHANGE
Target $14
SBSH
Buy
Lexicon price target lowered to $14 from $26 at Citi
Citi analyst Yigal Nochomovitz lowered his price Lexicon Pharmaceuticals (LXRX) to $14 following last week's FDA panel on sotagliflozin. The analyst now believes Sanofi (SNY) and Lexicon will likely need to conduct a pilot study on a Risk Evaluation and Mitigation Strategies program for mitigating diabetic ketoacidosis risk before the FDA will consider approving the drug. He keeps a Buy rating on Lexicon.
SLF Sun Life Financial
$37.95

-0.31 (-0.81%)

12/31/18
ARGS
12/31/18
UPGRADE
Target $39
ARGS
Buy
Sun Life Financial upgraded to Buy from Hold at Argus
Argus analyst Jacob Kilstein upgraded Sun Life Financial to Buy with a $39 price target.
12/31/18
ARGS
12/31/18
UPGRADE
Target $39
ARGS
Buy
Sun Life Financial upgraded to Buy at Argus on valuation
Argus analyst Jacob Kilstein upgraded Sun Life Financial (SLF) to Buy from Hold with a price target of $39, saying the company's valuation has become attractive after an 18% decline in the stock price since his last published report. The analyst cites Sun Life Financial's consistently strong earnings and above peer average ROE, along with some of its recent "small acquisitions" that should boost its earnings. Kilstein adds that his price target on the stock implies a forward earnings multiple of 10.5-times, which is still below the peer average of 11.7% valuation seen in the likes of Aflac (AFL) and Primerica (PRI).
03/14/19
CIBC
03/14/19
DOWNGRADE
CIBC
Underperformer
Sun Life Financial downgraded to Underperformer from Neutral at CIBC
CIBC analyst Paul Holden downgraded Sun Life Financial to Underperform from Neutral and raised its price target to C$54 from C$53.
02/06/19
SCOT
02/06/19
DOWNGRADE
SCOT
Sector Perform
Sun Life Financial downgraded to Sector Perform from Outperform at Scotiabank
YUMC Yum China
$40.96

-0.01 (-0.02%)

08/17/18
OPCO
08/17/18
DOWNGRADE
OPCO
Perform
Yum China downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Brian Bittner downgraded Yum China to Perform from Outperform, telling investors in a research note that the need for improving SSS could take several quarters as KFC headwinds do not appear transitory. Bittner contends that recent reports of takeout speculation in China present an interesting angle, but at a 23x forward P/E against elevated near-term operating risks.
03/14/19
DAIW
03/14/19
DOWNGRADE
DAIW
Outperform
Yum China downgraded to Outperform from Buy at Daiwa
Daiwa analyst Adrian Chan assumed coverage on Yum China with an Outperform from Buy and lowered its price target to $41 from $45. The analyst changed his view citing valuation but says long-term growth remains intact.
10/31/18
BOFA
10/31/18
UPGRADE
BOFA
Neutral
Yum China upgraded to Neutral from Underperform at BofA/Merrill
08/17/18
08/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dean Foods (DF) downgraded to Underweight from Neutral at JPMorgan with analyst Ken Goldman citing a "number of concerns," including a possible miss for Q3, higher raw milk costs, demand erosion for fluid milk, the risk of further customer attrition, and valuation. 2. Wabtec (WAB) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying he thinks risk/reward has become more balanced in the context of macro and forecasting risk, GE Transport (GE) integration risk and forward valuation. 3. Yum China (YUMC) downgraded to Perform from Outperform at Oppenheimer with analyst Brian Bittner saying needed improving same-store sales could take several quarters as KFC headwinds do not appear transitory. 4. DSW (DSW) downgraded to Negative ahead of expected guidance cut at Susquehanna with analyst Sam Poser saying he expects margins to be challenged due to increased variable costs and gross margin pressure related to the new loyalty program. 5. Sun Communities (SUI) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LN Line Corp.
$34.30

-1.23 (-3.46%)

02/08/19
GSCO
02/08/19
DOWNGRADE
GSCO
Sell
Line Corp. downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Masaru Sugiyama downgraded Line Corp. to Sell from Neutral and lowered his price target on the stock to Y2,900 from Y3,600, stating that he previously expected Line's advertising business to continue to drive monetization but he now believes the company is facing greater challenges on monetization from increasing advertising volumes alone. He also believes the cash burn will rise significantly going forward given the competitive landscape.
01/18/19
JEFF
01/18/19
DOWNGRADE
JEFF
Underperform
Line Corp. downgraded to Underperform from Hold at Jefferies
Jefferies analyst Atul Goyal downgraded Line Corp. back to Underperform saying the company is facing "large losses."
03/14/19
FBCO
03/14/19
DOWNGRADE
FBCO
Underperform
Line Corp. downgraded to Underperform from Neutral at Credit Suisse
02/25/19
EVER
02/25/19
INITIATION
EVER
Outperform
Line Corp. initiated with an Outperform at Evercore ISI
NBR Nabors Industries
$3.49

-0.005 (-0.14%)

03/14/19
SBSH
03/14/19
DOWNGRADE
SBSH
Neutral
Nabors Industries downgraded to Neutral from Buy at Citi
03/10/19
GSCO
03/10/19
INITIATION
Target $4
GSCO
Neutral
Nabors Industries initiated with a Neutral at Goldman Sachs
Goldman Sachs started Nabors Industries with a Neutral rating and $4 price target.
02/27/19
ARGS
02/27/19
DOWNGRADE
ARGS
Sell
Argus downgrades Nabors Industries to Sell, drops coverage
As previously reported, Argus analyst David Coleman downgraded Nabors Industries to Sell from Hold and dropped coverage of the company. "We are continuously reviewing the stocks in our coverage universe in order to provide research on those that appear most promising to our analysts and that generate the most interest among our clients. After several months of discussion, the director of research has concluded that NBR no longer meets these criteria," Coleman wrote in his downgrade note.
03/14/19
SBSH
03/14/19
DOWNGRADE
Target $4
SBSH
Neutral
Citi downgrades Nabors to Neutral on back half weighted outlook
Citi analyst Scott Gruber downgraded Nabors Industries (NBR) to Neutral from Buy and cut his price target for the shares to $4.00 from $6.70. The analyst coupled the downgrade with an upgrade of Forum Energy (FET) to Buy from Neutral. Nabors' free cash flow outlook is weighted towards the second half of 2019, with Q1 likely to be a cash burn of $40M-plus, Gruber tells investors in a research note. He believes the magnitude of the cash burn in Q1 will lead to investors questioning if the company can reach its $200M-$250M free cash flow target for the year. With the shares up 70% year-to-date, Gruber expects a "pause" into Nabors' Q1 results. The analyst's top three picks in U.S. Oil Services are Patterson-UTI (PTEN), Keane Group (FRAC) and Forum Energy.

TODAY'S FREE FLY STORIES

GE

General Electric

$10.04

-0.2 (-1.95%)

21:05
06/17/19
06/17
21:05
06/17/19
21:05
Periodicals
General Electric to cut another 450 jobs in Switzerland, Reuters says »

General Electric will lay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$86.25

-1.52 (-1.73%)

20:00
06/17/19
06/17
20:00
06/17/19
20:00
Hot Stocks
Arthur J. Gallagher acquires P2 Group, terms not stated »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

AGLNF

AGL Energy

$0.00

(0.00%)

19:28
06/17/19
06/17
19:28
06/17/19
19:28
Upgrade
AGL Energy rating change at Macquarie »

AGL Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

, RUN

Sunrun

$17.09

0.64 (3.89%)

19:02
06/17/19
06/17
19:02
06/17/19
19:02
Upgrade
SunPower, Sunrun, SolarEdge rating change at Goldman Sachs »

SunPower, Sunrun upgraded…

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

SEDG

SolarEdge

$56.58

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

, PHAS

PhaseBio

$12.25

0.74 (6.43%)

18:48
06/17/19
06/17
18:48
06/17/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: MoneyGram (MGI)…

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

PHAS

PhaseBio

$12.25

0.74 (6.43%)

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

STLD

Steel Dynamics

$26.23

-0.19 (-0.72%)

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

CALA

Calithera Biosciences

$5.87

0.64 (12.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 18

    Jun

  • 19

    Jun

AAPL

Apple

$193.90

1.06 (0.55%)

18:44
06/17/19
06/17
18:44
06/17/19
18:44
Periodicals
Apple's tvOS 13 beta 2 includes Picture-in-Picture support, 9to5Mac reports »

Apple's tvOS 13 beta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$56.58

0.09 (0.16%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SolarEdge rating change at Goldman Sachs »

SolarEdge upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$17.09

0.64 (3.89%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
Sunrun rating change at Goldman Sachs »

Sunrun upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SunPower rating change at Goldman Sachs »

SunPower upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:32
06/17/19
06/17
18:32
06/17/19
18:32
Hot Stocks
Bluescope Steel cuts FY19 EBIT growth view to up 6% from up 10% »

BlueScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$147.54

-1.25 (-0.84%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Hot Stocks
International Flavors CEO: We have planned for Brexit and China is benign for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.63

-0.65 (-1.12%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Periodicals
Senator aims to bar Huawei from seeking damages in patent courts, Reuters says »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:12
06/17/19
06/17
18:12
06/17/19
18:12
Hot Stocks
Breaking Hot Stocks news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$39.00

1.46 (3.89%)

18:04
06/17/19
06/17
18:04
06/17/19
18:04
Hot Stocks
Dish launches OnTech Smart Services »

Dish announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.30

-0.06 (-0.19%)

18:03
06/17/19
06/17
18:03
06/17/19
18:03
Hot Stocks
AT&T wins 24 GHz spectrum following FCC Auction 102 »

AT&T is the winning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:02
06/17/19
06/17
18:02
06/17/19
18:02
Syndicate
Biohaven Pharmaceutical offers to sell $300M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$51.42

0.01 (0.02%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

18:01
06/17/19
06/17
18:01
06/17/19
18:01
Hot Stocks
Versum Materials shareholders approve merger with Merck KGaA »

Versum Materials (VSM)…

VSM

Versum Materials

$51.42

0.01 (0.02%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

VLO

Valero

$76.93

0.19 (0.25%)

18:00
06/17/19
06/17
18:00
06/17/19
18:00
Periodicals
Valero restarting Port Arthur, Texas refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VLO

Valero

$76.93

0.19 (0.25%)

17:59
06/17/19
06/17
17:59
06/17/19
17:59
Periodicals
Valero restarting Meraux, Louisiana refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

17:44
06/17/19
06/17
17:44
06/17/19
17:44
Hot Stocks
MoneyGram spikes almost 140% after blockchain company Ripple investment »

Money transfer company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

17:37
06/17/19
06/17
17:37
06/17/19
17:37
Downgrade
JinkoSolar rating change at UBS »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FCEL

FuelCell

$0.33

-0.0231 (-6.56%)

17:26
06/17/19
06/17
17:26
06/17/19
17:26
Earnings
FuelCell reports Q2 ($2.06), consensus ($2.24) »

Reports Q2 revenue $9.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

17:25
06/17/19
06/17
17:25
06/17/19
17:25
Hot Stocks
Breaking Hot Stocks news story on Rockwell Medical »

Rockwell Medical down 21%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

VRS

Verso

$17.91

-0.24 (-1.32%)

17:21
06/17/19
06/17
17:21
06/17/19
17:21
Hot Stocks
Verso adopts limited duration stockholder rights plan »

Verso announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHVKF

China Vanke Co

$0.00

(0.00%)

17:19
06/17/19
06/17
17:19
06/17/19
17:19
Downgrade
China Vanke Co rating change at Morgan Stanley »

China Vanke Co downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.